The combination of aflibercept with FOLFIRI has been shown to significantly prolong overall survival in patients with metastatic colorectal cancer (mCRC) after progression on oxaliplatin-based therapy. This trial evaluated the addition of aflibercept to oxaliplatin-based first-line treatment of patients with mCRC.
introduction
In patients with metastatic colorectal cancer (mCRC), first-line treatment options usually involve combination chemotherapy regimens comprising infusional fluorouracil (5-FU) and leucovorin plus either irinotecan (FOLFIRI) or oxaliplatin (FOLFOX) [1] . The addition of an anti-angiogenic agent is noted to modestly improve treatment outcome in the first-line setting. The anti-VEGF-A (vascular endothelial growth factor-A) antibody bevacizumab improves overall survival (OS) when combined first line with either the irinotecan/bolus 5-FU/folinic acid IFL regimen [2] or 5-FU/folinic acid [3] . The combination of bevacizumab with an oxaliplatin-based regimen was associated with longer progression-free survival (PFS) in the first-line setting, but OS differences did not reach statistical significance, and response rate was not improved by the addition of bevacizumab [4] . In the treatment of second-line mCRC, the addition of bevacizumab to FOLFOX4 has been shown to improve OS in a bevacizumab-naïve population previously treated with irinotecan/ 5-FU [5] . The ML18147 study has demonstrated the benefit of continuing bevacizumab, with a concomitant switch in the chemotherapy backbone, in mCRC patients who had progressed on a prior combination of an alternative chemotherapy backbone plus bevacizumab [6] .
Aflibercept (VEGF-trap, US: ziv-aflibercept) is a recombinantly produced, fusion protein binding all isoforms of human VEGF-A, VEGF-B and the placental growth factor (PlGF). It interferes with the biological actions of VEGF by complexing VEGF and preventing it from interacting with its receptors on endothelial cells [7] . Furthermore, clinical data from the multicenter, randomized, placebo-controlled, phase III VELOUR trial, demonstrated a significant benefit from the addition of aflibercept to FOLFIRI in terms of median OS, PFS and response rate in patients with mCRC who had progressed on prior oxaliplatin-based therapy [8] . Moreover, this survival benefit was noted both in patients who were bevacizumab-naïve and those who were previously treated with bevacizumab [8, 9] .
The present randomized, phase II AFFIRM study reports on the efficacy and safety of aflibercept in combination with a modified FOLFOX6 regimen (mFOLFOX6) when used in the first-line setting for the treatment of patients with mCRC.
methods
AFFIRM was a randomized, open-label phase II study of aflibercept in addition to the modified (m) FOLFOX6 regimen or mFOLFOX6 alone as firstline treatment in patients with mCRC. Further patient inclusion criteria are described in supplementary Methods, available at Annals of Oncology online.
Patients were centrally randomized via an interactive voice response system using permuted block randomization stratified by Eastern Cooperative Oncology Group (ECOG) performance status (0-1 versus >1), previous adjuvant therapy (yes or no) and liver metastases only (yes or no).
All Imaging for tumor assessments was carried out every 8 weeks until disease progression (according to investigator assessment) and centrally reviewed by an Independent Review Committee (IRC) blinded to study treatment and carried out according to RECIST 1.0. All time-dependent events were calculated from randomization. Adverse events (AEs) were reported using the Medical Dictionary for Regulatory Activities (MedDRA) version 14.0 and toxicity was graded according to NCI common toxicity criteria (NCI-CTC) version 3.0.
The primary objective of the study was to estimate the PFS rate at 12 months according to central review. The trial was not powered to demonstrate superiority of one treatment arm over the other. As a pre-planned exploratory analysis, the Kaplan-Meier estimates for PFS and OS were computed for each treatment group. The hazard ratios (aflibercept versus control) and 95% confidence interval (CI) were estimated using the Cox proportional hazards model, after adjusting according to the above-mentioned stratification factors. Overall response rate (ORR) was estimated in each treatment group.
The anticipated median PFS in the mFOLFOX6 arm was 8.5 months. A risk reduction of 23% was expected in the aflibercept/mFOLFOX6 arm, corresponding to a median PFS of 11 months or a PFS rate of 46.9% at 12 months for aflibercept/mFOLFOX6 and 37.6% for mFOLFOX6. Considering 9.4% precision for the 95% CI, 110 patients per arm were required. The total number of patients required was estimated to be 230 allowing for 10 patients being lost to follow-up. With this precision, the lower limit of the 95% CI of the estimated PFS at 12 months in the aflibercept/mFOLFOX6 group was to be at least equal to the PFS at 12 months expected in the mFOLFOX6 arm. The final analysis was planned 1 year after the randomization of the last patient.
The study was approved by each recruiting center's ethics committee and the corresponding health authority. All patients provided signed informed consent to participate in the study before any study procedures were carried out.
results

patient population
Between March 2009 and April 2010, 236 patients were enrolled from 36 centers in Australia, Germany, Italy, Republic of Korea, Russian Federation, Spain and UK. One hundred and nineteen patients were randomized to receive aflibercept/mFOLFOX6, and 117 patients to receive mFOLFOX6 alone. According to the protocol, 235 patients were included in the safety population, and 227 patients were evaluable for the primary efficacy analysis (PFS according to central review, CONSORT diagram, supplementary Figure S1 , available at Annals of Oncology online). Of these 227 patients, 93 (40.9%) provided samples of tumor DNA for genetic mutation profiling, 47 (50.5%) of whom had been treated with aflibercept. Thirty-one patients (33%) had tumors with a KRAS mutation, three patients (3%) a BRAF and three patients (3%) a NRAS mutation [10] .
Overall, 97.0% of patients had an ECOG performance status of 0 or 1. The median age was 62.5 (29-87) years. Almost 10% of patients had received prior adjuvant therapy, 61.0% of patients were male and 25.8% had liver only metastases. There were no major differences in patients' characteristics across the treatment arms (Table 1) .
Alkaline phosphatase levels were raised in over one-third of all patients at baseline with an equal distribution between the two treatment arms.
drug exposure
The median number of aflibercept cycles was 7.0 (range 1-43). In the mFOLFOX6 and the aflibercept/mFOLFOX6 arms, the median number of oxaliplatin cycles was 10.0 (1-31) and 9.0 (1-40), and the median number of 5-FU cycles was 11.0 (1-43) and 10.0 (1-44), respectively (supplementary Figure S2 , available at Annals of Oncology online). The median duration of exposure to aflibercept was 17.1 weeks (range 2-94). In the mFOLFOX6 and the aflibercept/mFOLFOX6 arms, the median duration of exposure to oxaliplatin was 23.2 (2-77) and 22.0 (2-84), and to 5-FU was 25.9 (2-95) and 24.1 (2-106) weeks, respectively. At the time of analysis, all patients had discontinued study medication. The most frequent reasons for mFOLFOX6 and aflibercept/mFOLFOX6 discontinuation were disease progression (44.4% and 39.5%), AEs (22.2% and 30.3%), investigator's decision (11.1% and 11.8%), patient's request (9.4% and 10.1%) and metastatic surgery (5.1% and 5.0%), and for other reasons in 6.8% and 3.4% of patients, respectively.
treatment efficacy
The probability of being progression-free at 12 months was 21.2% (95% CI 12.2-30.3) in the mFOLFOX6 arm and 25.8% (95% CI 17.2-34.4) in the aflibercept/mFOLFOX6 arm, and was lower than anticipated in both arms. For PFS, there were 79 (71.2%) and 93 (80.2%) patients with events in the mFOLFOX6 and aflibercept/mFOLFOX6 arms, respectively. The median PFS was 8.77 months (95% CI 7.62-9.27) for the mFOLFOX6 arm and 8.48 months (95% CI 7.89-9.92) for the aflibercept/mFOLFOX6 arm [stratified HR of mFOLFOX6 versus aflibercept/mFOLFOX6 1.00 (95% CI 0.74-1.36) (Figure 1) (Table 2) . Laboratory abnormalities were only reported as treatment-emergent AEs if they led to study discontinuation, dose modification or fulfilled a seriousness criterion. Most frequent grade ≥3 AEs in the experimental arm excluding laboratory abnormalities were neutropenia (36.1% versus 29.3%), hypertension (35.3% versus 1.7%), peripheral neuropathy (16.8% versus 17.2%) and diarrhea (13.4% versus 5.2%). The frequency of febrile neutropenia was less for patients receiving mFOLFOX6 alone (3.4%) than for those receiving aflibercept/ mFOLFOX6 (5.9%). Laboratory results showed a higher incidence of grade 3/4 neutropenia in the aflibercept/mFOLFOX6 group than in the mFOLFOX6 group (42.7% versus 31.0%, supplementary Table S1 , available at Annals of Oncology online). One patient in the mFOLFOX6 arm and five patients treated with aflibercept/mFOLFOX6 died within 30 days of their last dose of treatment due to AEs not regarded as disease progression. One patient had an unrelated intracranial hemorrhage after 16 cycles (aflibercept had been discontinued after cycle 7); all remaining patients died due to infections. All but one of these (staphylococcal sepsis during cycle 14, aflibercept had been discontinued after cycle 2) were judged by the investigator as not related to study treatment.
Grade ≥3 toxicities in the experimental arm considered to be a class effect of VEGF inhibition were hypertension (35.3% versus 1.7%), proteinuria (9.2% versus 0%), deep vein thrombosis (5.9% versus 0.9%), pulmonary embolism (5.9% versus 5.2%) and epistaxis (1.7% versus 0%). Other AEs of note were rectal hemorrhage (0.8% versus 0%) and dysphonia grade 1-2 which was reported in only 2.6% of patients in the 
discussion
Aflibercept and other anti-angiogenic treatments have been shown to prolong OS in pretreated patients with mCRC [5, 6, 11, 12] .
In the VELOUR study, compared with chemotherapy alone, adding aflibercept to FOLFIRI significantly improved OS in patients in whom an oxaliplatin-containing regimen had previously failed (median 13.5 versus 12.1 months, HR 0.82; 95% CI 0.71-0.94) [8] .
In the present AFFIRM study, PFS rate at 12 months was the primary end point. This PFS rate was lower than expected for original articles Annals of Oncology both arms. Although the trial was not powered to demonstrate superiority, no difference was observed between the two treatment groups for PFS at 12 months (25.8% versus 21.2%), median PFS (8.48 months versus 8.77 months) or response rate (49.1% versus 45.9%) for patients treated with and without aflibercept, respectively. The study was not designed to detect differences in OS, and the follow-up time for OS was probably too short to draw firm conclusions. In AFFIRM, most patients were not treated until disease progression; the median number of cycles was 11 and 10 for the mFOLFOX6 and aflibercept/mFOLFOX6-treated arms, respectively-shorter than the median PFS of 8.77 and 8.48 months. Only 44% and 39% of patients in the mFOLFOX6 and aflibercept/mFOLFOX6 arms discontinued treatment due to progressive disease, and a further 5% of patients due to metastasectomy. The remaining percentage of patients who discontinued treatment is only partly explained by AEs (more frequent with aflibercept/mFOLFOX6 than with mFOLFOX6, 30.3% versus 22.2%) and may reflect the opinion of investigators that treatment beyond 6 months would be of limited benefit [13] . These relatively short treatment durations have been observed in several recent colorectal cancer trials, including those in which the trial protocol recommended treatment until tumor progression, e.g. FIRE-3, comparing the FOLFIRI combination with cetuximab or bevacizumab (median duration of treatment for all study agents 5.3 or 4.8 months, respectively) [14] and in the NO16966 trial (oxaliplatin-based chemotherapy with or without bevacizumab, treatment duration 190 and 176 days, respectively) [4] . The interval between the median treatment duration and the median PFS is similar to the intervals reported for the treatment holidays ( planned treatment pause until progression) in the CAIRO3 and AIO-KRK 0207 trials [15, 16] . In the NO16966 trial (oxaliplatin-based chemotherapy plus/minus bevacizumab) [4] , it was calculated, that the difference in PFS between the treatment arms might have been larger if all patients in both arms had been treated until progression [4] . The median 'on-treatment PFS' for the NO16966 trial was 10.4 months with chemotherapy plus bevacizumab versus 7.9 months with chemotherapy plus placebo (HR, 0.63; 97.5% CI 0.52-0.75; P = 0.0001). However, treatment until progression in all patients does obviously not reflect clinical practice even though it was planned, e.g. in the AFFIRM, NO16966 and FIRE3 trials. The absence of significant differences in response rate and OS is consistent with all trials investigating anti-VEGF strategies in combination with first-line oxaliplatin-based schedules (Table 3) . Furthermore, a significant survival benefit from the addition of an anti-VEGF drug has only been demonstrated first line in mCRC with fluoropyrimidine monotherapy [3, 16] and the IFL regimen [2] , the latter of which is rarely if ever used in the current era. Unfortunately, unlike KRAS/NRAS for EGFR-targeting antibodies, no predictive biomarkers for the benefit of VEGF inhibitors with any chemotherapy backbone have yet been identified [14, 17] . In AFFIRM, treatment outcomes with aflibercept appear to be independent of (K)RAS mutation status and other biomarkers [10] .
Aflibercept, in combination with FOLFIRI, has shown efficacy for patients with mCRC that is resistant to or has progressed following an oxaliplatin-containing regimen. In the AFFIRM trial, adding aflibercept to FOLFOX-based first-line therapy did not increase efficacy but was associated with higher toxicity. This is consistent with the observations made with other antiangiogenic agents in combination with FOLFOX in the first-line setting.
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